Form 4: Solventum Director John Weiland Receives RSU Grant

Director John H. Weiland was granted 3,300 restricted stock units in Solventum Corp, vesting in May 2027.

Summary

• Director John H. Weiland received a grant of 3,300 Restricted Stock Units (RSUs) on May 15, 2026.
• Each RSU represents a contingent right to receive one share of Solventum Corp common stock upon settlement.
• The RSUs are scheduled to fully vest on May 15, 2027, contingent upon continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in nature.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is subject to continued service requirements through May 15, 2027.

Future Outlook

The director is expected to maintain service through the vesting date of May 15, 2027, to realize the equity grant.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice to ensure board members maintain a vested interest in the company's long-term performance.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for large-cap healthcare and technology companies.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• Vesting of 3,300 RSUs on May 15, 2027.

Key Dates

Keywords

Solventum, SOLV, Form 4, Insider Trading, Director Compensation, Restricted Stock Units